BRCA1 and ovarian carcinoma: In 2017, the working group decided to perform a survey sending two different questionnaires: The first to the Departments of Medical Oncology, and the second to the Diagnostic Laboratories performing the BRCA1/2 assay in order to gain information about the pathways that ovarian cancer patients follow in Italy to undergo these molecular tests.